Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacterial Load Guided Therapy for Bronchiectasis Exacerbations
NCT02047773Phase 4Completed
- Sponsor
- University of Edinburgh
- Start
- Jan 2014
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of meropenem in bronchiectasis (2 arms), sponsored by University of Edinburgh. Primary endpoints: Time to next exacerbation at 1 year and Proportion of patients that stopped antibiotics early at 14 days. Started Jan 2014; status: completed.
02
Drugs
meropenem
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT02047773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047773.